Ifosfamide- and paclitaxel-based treatment of relapsed and refractory lymphoma.
Several trials of new salvage therapies for relapsed and refractory non-Hodgkin's lymphoma are based on ifosfamide and paclitaxel. These programs variably Induce clinical remissions and prepare patients for stem cell and bone marrow transplantations. Ifosfamide-containing regimens are also being evaluated in the treatment of newly diagnosed patients. However, no data exist with regard to paclitaxel-containing regimens outside salvage settings. This report reviews the effects of these compounds in the treatment of relapsed and refractory non-Hodgkin's lymphoma and proposes likely directions for future study.
King
K
K
Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Younes
A
A
D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage* / Q000627:therapeutic use; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage; D016879:Salvage Therapy
D018906:Antineoplastic Agents, Alkylating; D017239:Paclitaxel; D007069:Ifosfamide